Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer.
Koniaris
Leonidas G
LG
Department of Surgery, Sylvester Comprehensive Cancer Center, The University of Miami, Miami, FL, USA. lkoniaris@med.miami.edu
Jin
Xiaoling
X
Montero
Alberto J
AJ
Zimmers
Teresa A
TA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016207:Cytokines / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D009363:Neoplasm Proteins / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016601:RNA-Binding Proteins / Q000008:administration & dosage; D015996:Survival Rate; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; C077219:small inducible cytokine subfamily E, member 1; D003841:Deoxycytidine; D000068258:Bevacizumab; D000093542:Gemcitabine